Science news

<<  return


REWIND: Once-Weekly GLP-1 Agonist Cuts CVD in Type 2 Diabetes

The once-weekly injectable glucagon-like peptide 1 (GLP-1) agonist dulaglutide (Trulicity, Lilly) for the treatment of type 2 diabetes has significantly reduced the risk of major adverse cardiovascular events (MACE) in the REWIND trial, Lilly has announced, revealing the top-line results of the study today.

REWIND is the cardiovascular (CV) outcomes trial for dulaglutide and the first such study to include a majority of patients who did not have established cardiovascular disease (CVD) at baseline, the company says in a press release.

The MACE endpoint was a composite of CV death, nonfatal myocardial infarction (MI), or nonfatal stroke. The study compared the effect of once-weekly dulaglutide 1.5 mg, delivered subcutaneously, to placebo when added to standard of care in type 2 diabetes.

Full details of the REWIND study will be reported at the American Diabetes Association Scientific Sessions in San Francisco in 2019, the company says.